DIAN DIAGNOSTICS(300244)2023-10-27 16:00Financial Performance - The company's operating revenue for the reporting period was ¥3,450,329,131.36, a decrease of 29.25% compared to the same period last year[4]. - The net profit attributable to shareholders was ¥77,585,726.19, down 85.84% year-on-year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥150,052,828.69, a decrease of 71.88% compared to the previous year[4]. - The company's basic earnings per share were ¥0.1237, down 85.98% year-on-year[4]. - Total operating revenue for the third quarter was ¥10,292,194,930.88, a decrease of 34.5% compared to ¥15,629,585,233.35 in the same period last year[26]. - Net profit attributable to the parent company was ¥791,430,012.31, compared to ¥530,878,904.74 in the previous year, reflecting a significant increase[26]. - Basic earnings per share for the quarter was ¥0.8468, down from ¥3.9093 in the same quarter last year[26]. - Net profit for the quarter was approximately 2.87 billion in the same period last year[45]. - The company reported a decrease in total profit from 1.02 billion, a decline of about 69.9%[45]. Cash Flow - The net cash flow from operating activities was ¥366,809,423.96, an increase of 597.92% year-on-year[4]. - Cash flow from operating activities totaled ¥11,964,595,499.94, slightly down from ¥12,086,152,872.35 year-over-year[26]. - The company’s cash flow from operating activities was impacted by a decrease in cash received from sales of goods and services, which totaled ¥11,776,855,579.27 compared to ¥11,891,901,448.05 in the previous year[26]. - Cash flow from operating activities generated a net inflow of approximately 52.56 million in the previous year, showing a substantial increase[49]. - Cash flow from investing activities resulted in a net outflow of approximately 657.85 million in the same period last year[49]. - Cash flow from financing activities showed a net outflow of approximately 539.79 million in the previous year, indicating a significant change in financing strategy[49]. Assets and Liabilities - Total assets at the end of the reporting period were ¥18,745,645,969.00, a decrease of 10.97% from the end of the previous year[4]. - The total assets of the company decreased from CNY 21,055,969,393.06 to CNY 18,745,645,969.00, representing a decline of approximately 10.4%[21]. - Current liabilities increased significantly from CNY 5,220,930,409.32 to CNY 7,747,956,631.67, indicating a rise of about 48.4%[21]. - The company's long-term equity investments decreased from CNY 1,084,061,200.68 to CNY 683,119,528.21, a drop of about 37.0%[21]. - The total non-current assets decreased from CNY 4,267,261,748.15 to CNY 4,095,654,534.05, a decline of approximately 4.0%[21]. - The company reported a significant decrease in short-term borrowings from CNY 1,941,202,714.91 to CNY 1,061,840,883.34, a reduction of about 45.2%[21]. - The company's total liabilities decreased to ¥8,355,751,521.04 from ¥11,553,970,724.28, indicating a reduction in financial leverage[26]. - Total equity increased to ¥10,389,894,447.96 from ¥9,501,998,668.78, showing a growth in shareholder value[26]. Expenses - The company reported a significant reduction in management expenses by 34.02% to ¥650,875,968.76, attributed to cost-cutting strategies[14]. - Research and development expenses decreased by 33.71% to ¥320,484,020.33, reflecting a controlled pace of investment in selected projects[14]. - R&D expenses for the quarter were approximately 483.46 million in the previous year, reflecting a decrease of about 33.7%[45]. - Financial expenses totaled approximately 222.75 million, indicating a reduction of about 24%[45]. Shareholder Information - The company has a total of 29,545 common shareholders, with the largest shareholder holding 26.23% of the shares[16]. Future Outlook - The company plans to continue its market expansion and product development strategies, although specific figures were not disclosed in the provided content[22].